About NanoPin.The NanoPin team shares a vision to improve the lives of those afflicted with infectious disease throughout the world.
|
Established in 2017NanoPin Technologies incorporated on April 20, 2017 by Dr. Tony Hu and Dr. Thomas Tombler with a commitment to realize the commercialization of an innovative technology in disease diagnosis.
|
Our GoalAt NanoPin Technologies, our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious disease epidemics such as tuberculosis (historically the leading cause of death from infectious disease worldwide), HIV, and COVID-19.
|
Our Team
Thomas Tombler, PhD, MBA
|
Christopher Lyon, PhD
|
Wael Abdelgaliel, PhD
|
Xiao-Ming Yin, MD, PhD, FAASLD, FCAP
Board of Advisor Member – Clinical Laboratory Services Dr. Yin is the Dr. Donald R. Pulizer and Donna G. Pulitzer Professor of the Department of Pathology and Laboratory Medicine at Tulane University School of Medicine. He graduated from Fudan University Shanghai Medical College with an MD and from University of Texas Southwestern Medical Center at Dallas with a PhD, and received his clinical pathology training at Washington University at St Louis. He is a board-certified pathologist with more than two decades of experience in molecular diagnostics and clinical laboratory operations. He has served as CLIA/CAP-designated director for multiple clinical laboratories that have up to 10 million sample volumes annually. As the Medical consultant and clinical laboratory advisor to NanoPin, Dr. Yin guides our clinical and regulatory strategies for our current and future diagnostic services to include COVID-19, tuberculosis, HIV, NTM and more. |
Wilson Zhang, M.D.
Board of Advisor Member Dr. Wilson Zhang is a leading figure in the vitro diagnostics industry with over 20 years of experience. Wilson formerly served as the Lead of Strategy and Business Development at Zhejiang Dian Diagnostics Co., one of the largest diagnostic labs in the world, focusing on establishing strategic collaborations with international and domestic IVD companies. Dr. Zhang holds an M.D. from Shanghai Jiaotong University School of Medicine, an M.Sc. from Rivier University, and executive education at Dartmouth College’s Tuck School of Business. |
Elisha is an American Society for Clinical Pathology certified Medical Laboratory Scientist with a clinical laboratory background in molecular pathology, flow cytometry and electrophoresis. Her primary focus has been working with various infectious agents that have a great impact on human health, particularly in the New Orleans area.
She earned her Master’s of Science in Public Health with a concentration in Tropical Medicine degree from Tulane University School of Public Health and Tropical Medicine, and her Medical Laboratory Science degree from Louisiana State University School of Allied Health Professions. |
|
|
Science Advisor Professor Tony HuAs NanoPin’s technology is derived from the research group of Professor Tony Hu, we are pleased that Professor Hu serves as NanoPin’s Science Advisor. Dr. Hu is the Weatherhead Presidential Chair in Biotechnology Innovation at Tulane University and Director of Tulane’s Center of Cellular and Molecular Diagnosis. He is a leading researcher in the fields of marker discovery, molecular diagnostics, and nanotechnique-based strategies for biomedical advancement. Dr. Hu’s research has focused on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations fill current gaps in early detection, real-time therapy monitoring and effective prognostics. He has assembled a diverse team with backgrounds in biochemistry, mass spectrometry, nanofabrication, and biomedical engineering to answer these needs.
Dr. Hu received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. He is extensively published in premier high impact journals and his research team has a history of major grants from the NCI, NIAID, NICHD and DOD and awards from the Gates, Dunn, Kostas, and Cockrell family foundations. His expertise includes in-depth knowledge of multiplex-detection method development for sample processing, mass spectrometry, biomarker identification and validation. Dr. Hu’s background ideally positions him for leadership in these fields and for optimal clinical translation of their platforms for improved and comprehensive analysis of blood-based biomarkers that have broad potential clinical applications. |